Synbiotics Interventions for Managing Cirrhosis and Its Complications

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 24, 2019

Primary Completion Date

May 24, 2021

Study Completion Date

October 24, 2022

Conditions
Cirrhosis, LiverMetagonimiasis
Interventions
DRUG

Entecavir 0.5 mg

Orally administered Entecavir 0.5 mg, once a day. For six months

DRUG

A 10-g packet of lactulose oral solution and three capsules of probiotics

"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."

DIETARY_SUPPLEMENT

A 10-g packet of glucose oral solution and three capsules of starch

A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.

Trial Locations (1)

Unknown

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER

NCT05687409 - Synbiotics Interventions for Managing Cirrhosis and Its Complications | Biotech Hunter | Biotech Hunter